logo
logo

Ikonisys Announces The Completion Of New Financing Via The Issuance Of A €0.5M Private Note

Aug 03, 2023about 2 years ago
Paris

Investors

Columbia Threadneedle InvestmentsLpe Ii Lp

Description

Regulatory News:

Company Information

Company

Ikonisys

Location

Paris, Ile De France, France

About

Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease. Through its breakthrough fluorescence microscopy platform, Ikonisys continues to develop a stream of oncology tests for a variety of cancers. At the center of the platform is the Ikoniscope20®, a robotic, high-throughput, microscopy system that provides a true “walk away” automated solution. In addition to providing high quality cell images, the platform analyzes the cells of interest, offering an interpretation of the analysis, to facilitate the quick, accurate reporting of the test result. In addition to automating traditional FISH-based tests, the rare cell detection and analysis capabilities of the platform, that facilitates the examination of large complex samples for the clinically relevant cells, make it particularly suitable for circulating tumor cell-based testing.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers